RT Journal Article
SR Electronic
T1 A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1471
OP 1477
VO 38
IS 3
A1 JINAN GUO
A1 JIANGGEN YANG
A1 XUHUI ZHANG
A1 XIAOYAN FENG
A1 HEQIU ZHANG
A1 LINGWU CHEN
A1 HEATHER JOHNSON
A1 JENNY L. PERSSON
A1 KEFENG XIAO
YR 2018
UL http://ar.iiarjournals.org/content/38/3/1471.abstract
AB Background/Aim: Prostate cancer (PCa) diagnosis using patient urine samples represents a non-invasive and more convenient method than the conventional biopsy and prostate-specific antigen (PSA) test. This study intended to identify a biomarker panel to distinguish PCa from benign prostate using urine samples. Materials and Methods: We identified six biomarkers with differential gene expression in 154 PCa and benign prostate specimens. We then determined mRNA expression signature and the diagnostic performance of the 6-biomarker panel in 156 urine samples from patients with PCa and benign disease. Results: The 6-biomarker panel distinguished PCa from benign prostate cases with sensitivity of 80.6%, specificity of 62.9% and area under the curve (AUC) of 0.803 (p<0.0001), whereas serum PSA at 4 ng/ml cutoff had sensitivity of 95.5%, specificity of 20.2% and AUC of 0.521 (p<0.0001). Conclusion: The 6-biomarker panel for use in urine samples was able to distinguish PCa from benign prostate with higher specificity and accuracy than PSA and may be useful in clinical settings.